The QOL Analysis Of Hyperthermic Intrapeirtoneal Perfusion Chemotherapy For Ovarian Cancer

PurPose:1To study the impact on the quality of life(QOL) of patients accepting thehyperthermic intraperitoneal perfusion chemotherapy(HIPC) combined with intravenouschemotherapy the quality of life(QOL) in ovarian cancer patients, both of HIPC combinedwith intravenous chemotherapy and of intravenous chemotherapy only.2To discuss the main adverse effect on the QOL of HIPC combined with intravenouschemotherapy.3. To study the different impact on the QOL of HIPC combined with intravenouschemotherapy and of intravenous chemotherapy only.Subjects and Methods:Chose the methods of collecting disease history and questionnaire survey. Collectedsixty patients with diagnosed ovarian cancer (OC), phase ⅡB to Ⅳ, whohad visited the JilinUniversity the1st hospital from June2008to June2011. Divided them into thirty patients(accepting HIPC combined with intravenous chemotherapy) as the treatment group, andthirty patients (accepting the intravenous chemotherapy only) as the control group. Theinvestigator helped the patients completed the European Organization for Research andTreatment of Cancer (EORTC) QLQ Questionnaire Core30the third printing block inChinese as the state of medical staff. Completed one questionnaire survey before therapy,and did the same at the2nd,7th and15th day of therapy-free interval. Every patient wasunder the same investigator’s guide for the four times in total. Did the linearity change ofscores by method of pole-difference, and change the Raw score into the standard score whichbetween0-100. Test all the patients CA-125before the chemotherapy, and blood routine，function of liver and kidney before and after the chemotherapy. All the results were handledby the statistics software of SPSS17.0. We treated p＜0.05as having statistics significance,and treated p＜0.01as having remarkable statistics significance.Results:1. In the fields of Physical Functioning, Role Functioning, Emotional Functioning,Cognitive Functioning, Social Functioning and Fatigue, the QOL of all the patients declinedfirst, then recovered after1week（P＜0.01）. 2. In the fields of Nausea and Vomiting, Appetite Loss and Global Health, the QOL ofpatients in the two groups declined first, then patients in the control group recovered in1week, and patients in the treatment group recovered in2weeks（P＜0.01）.3. In the treatment group, patients got the symptom of pain lasting more than2weeksafter the therapy（P＜0.01）, and got the symptom of diarrhea lasting less than1week afterthe therapy（P＜0.05）.4. In the fields of Physical Functioning, Role Functioning, Cognitive Functioning,Social Functioning, Global Health, Fatigue, Nausea and Vomiting, Appetite Loss andDiarrhea, the QOL of the patients in the treatment group were worse than the control groupin1week after the therapy, and recovered as the control group after2weeks except thefields of Physical Functioning and Global Health（P＜0.05）.5. Patients in the treatment group had a lower incidence of Stage Ⅲ,Ⅳ bloodytoxicity and damage of function of liver and kidney, and a higher1-year and2-year survivalrate（P＜0.05）.Conclusion:1. The HIPC combined with intravenous chemotherapy can cause the QOL of patientsdeclined in the fields of Physical Functioning, Role Functioning, Emotional Functioning,Cognitive Functioning, Social Functioning, Global Health, Fatigue, Nausea and VomitingAppetite Loss, Diarrhea.2. The QOL of patients acceptting HIPC combined with intravenous chemotherapyrecovered in2weeks.3. The QOL of patients acceptting HIPC combined with intravenous chemotherapywas worse than that acceptting intravenous chemotherapy only in the fields of RoleFunctioning, Cognitive Functioning, Social Functioning and Fatigue, Diarrhea within1week,and nearly the same after that.4. Using Nedaplatin for the therapy instead of cisplatin could improve the QOL.